Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 10/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311293 | 0.87 | HDAC1 (0.46) | HDAC1HDAC6PTGDR2CXCR4CYP2D6 | |
| SCHEMBL1698205 | 0.86 | HDAC1 (0.40) | HDAC1HDAC6PTGDR2CXCR4CYP2D6 | |
| SCHEMBL1698225 | 0.86 | HDAC1 (0.40) | HDAC1HDAC6PTGDR2CXCR4CYP2D6 | |
| SCHEMBL923694 | 0.83 | PTGDR2 (0.44) | HDAC1HDAC6PTGDR2CXCR4ADORA2A | |
| SCHEMBL24858718 | 0.80 | CYP2D6 (0.43) | HDAC1HDAC6CXCR4CYP2D6 | |
| SCHEMBL3314390 | 0.80 | HDAC1 (0.44) | HDAC1HDAC6CXCR4CYP2D6 | |
| SCHEMBL21202393 | 0.80 | CYP2D6 (0.43) | HDAC1HDAC6CXCR4CYP2D6 | |
| SCHEMBL21275417 | 0.79 | HDAC1 (0.42) | HDAC1HDAC6CXCR4CYP2D6CHRM3 | |
| SCHEMBL2725023 | 0.79 | HDAC1 (0.42) | HDAC1HDAC6CXCR4CYP2D6CHRM3 | |
| SCHEMBL3950796 | 0.79 | HDAC1 (0.43) | HDAC1HDAC6CXCR4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, CNR1, CNR2 | HDAC1 606/4885HDAC6 704/4885PTGDR2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.